LifeStance Health Group (NASDAQ:LFST) Given Overweight Rating at Morgan Stanley

Morgan Stanley reissued their overweight rating on shares of LifeStance Health Group (NASDAQ:LFST) in a research note published on Monday, Benzinga reports. The brokerage currently has a $10.00 target price on the stock.

Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group upped their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a buy rating in a research report on Wednesday, March 6th. The Goldman Sachs Group increased their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a neutral rating in a research report on Monday, March 4th. Finally, Barclays increased their price target on shares of LifeStance Health Group from $7.00 to $8.00 and gave the stock an underweight rating in a research report on Thursday, February 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, LifeStance Health Group has a consensus rating of Hold and a consensus price target of $8.83.

LifeStance Health Group Trading Up 2.8 %

Shares of LFST opened at $5.87 on Monday. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.20. LifeStance Health Group has a 12-month low of $4.74 and a 12-month high of $9.59. The firm has a 50-day moving average price of $6.48 and a 200 day moving average price of $6.54. The firm has a market capitalization of $2.23 billion, a P/E ratio of -11.51 and a beta of 1.34.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). LifeStance Health Group had a negative net margin of 17.64% and a negative return on equity of 12.66%. The company had revenue of $280.60 million during the quarter, compared to analyst estimates of $263.14 million. Sell-side analysts forecast that LifeStance Health Group will post -0.3 EPS for the current year.

Insider Buying and Selling

In related news, insider Kevin Michael Mullins sold 115,136 shares of LifeStance Health Group stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $8.02, for a total value of $923,390.72. Following the completion of the transaction, the insider now owns 4,575,480 shares in the company, valued at $36,695,349.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other LifeStance Health Group news, insider Danish J. Qureshi sold 12,965 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $5.93, for a total transaction of $76,882.45. Following the sale, the insider now owns 4,911,050 shares of the company’s stock, valued at $29,122,526.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kevin Michael Mullins sold 115,136 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $8.02, for a total transaction of $923,390.72. Following the sale, the insider now directly owns 4,575,480 shares in the company, valued at approximately $36,695,349.60. The disclosure for this sale can be found here. Insiders sold 245,463 shares of company stock worth $1,786,868 over the last 90 days. 8.50% of the stock is owned by insiders.

Institutional Trading of LifeStance Health Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Assetmark Inc. raised its holdings in LifeStance Health Group by 21.6% during the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock worth $93,000 after purchasing an additional 2,114 shares in the last quarter. Brown Advisory Inc. raised its holdings in LifeStance Health Group by 25.9% during the fourth quarter. Brown Advisory Inc. now owns 5,158,980 shares of the company’s stock worth $40,395,000 after purchasing an additional 1,062,887 shares in the last quarter. Principal Financial Group Inc. raised its holdings in LifeStance Health Group by 2.8% during the fourth quarter. Principal Financial Group Inc. now owns 4,006,344 shares of the company’s stock worth $31,370,000 after purchasing an additional 110,457 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in LifeStance Health Group by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 744,617 shares of the company’s stock worth $5,830,000 after purchasing an additional 5,112 shares in the last quarter. Finally, Stratos Wealth Partners LTD. acquired a new stake in LifeStance Health Group during the fourth quarter worth approximately $93,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.